Which has preferable valuation and earnings, DSGN or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Is DSGN or GPCR more profitable?

Structure Therapeutics' return on equity of -24.91% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Structure Therapeutics N/A -24.91% -23.67%

Does the media refer more to DSGN or GPCR?

In the previous week, Structure Therapeutics had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 5 mentions for Structure Therapeutics and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Structure Therapeutics' score of 0.78 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, IRON or DSGN?

Disc Medicine is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.62 N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is IRON or DSGN more profitable?

Design Therapeutics' return on equity of -33.07% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -36.94% -33.88% Design Therapeutics N/A -33.07% -31.29%

Does the media favor IRON or DSGN?

In the previous week, Disc Medicine had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 5 mentions for Disc Medicine and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Disc Medicine's score of 0.76 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARQT or DSGN?

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for Arcutis Biotherapeutics and 2 mentions for Design Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.18 beat Design Therapeutics' score of 0.94 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DSGN or IDYA more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% IDEAYA Biosciences N/A -14.24% -13.09%

Does the media refer more to DSGN or IDYA?

In the previous week, IDEAYA Biosciences had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 6 mentions for IDEAYA Biosciences and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat IDEAYA Biosciences' score of 0.56 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, DSGN or VERA?

Design Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A

Is DSGN or VERA more profitable?

Design Therapeutics' return on equity of -33.07% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Vera Therapeutics N/A -74.86% -60.18%

Does the media refer more to DSGN or VERA?

In the previous week, Vera Therapeutics had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Vera Therapeutics and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Vera Therapeutics' score of 0.91 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Design Therapeutics (DSGN) Competitors

$10.48 -0.26 (-2.42%)

Closing price 04:00 PM Eastern

Extended Trading

$10.33 -0.15 (-1.43%)

As of 05:40 PM Eastern

Compare

DSGN vs. GPCR, IRON, ARQT, IDYA, and VERA

Should you buy Design Therapeutics stock or one of its competitors? MarketBeat compares Design Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Design Therapeutics include Structure Therapeutics (GPCR), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), IDEAYA Biosciences (IDYA), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry.

How does Design Therapeutics compare to Structure Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 23.5% of Design Therapeutics shares are held by company insiders. Comparatively, 5.6% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Structure Therapeutics had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 5 mentions for Structure Therapeutics and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Structure Therapeutics' score of 0.78 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Design Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 57.44%. Structure Therapeutics has a consensus price target of $109.25, suggesting a potential upside of 177.71%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Structure Therapeutics' return on equity of -24.91% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Structure Therapeutics	N/A	-24.91%	-23.67%

Design Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.31, indicating that its share price is 231% less volatile than the broader market.

Summary

Structure Therapeutics beats Design Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Design Therapeutics (NASDAQ:DSGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Disc Medicine presently has a consensus price target of $105.30, indicating a potential upside of 51.36%. Design Therapeutics has a consensus price target of $16.50, indicating a potential upside of 57.44%. Given Design Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Design Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Design Therapeutics' return on equity of -33.07% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Design Therapeutics	N/A	-33.07%	-31.29%

In the previous week, Disc Medicine had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 5 mentions for Disc Medicine and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Disc Medicine's score of 0.76 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Disc Medicine is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Disc Medicine has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market.

Summary

Design Therapeutics beats Disc Medicine on 11 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Design Therapeutics (NASDAQ:DSGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

56.6% of Design Therapeutics shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 23.5% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market.

Design Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Design Therapeutics	N/A	-33.07%	-31.29%

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for Arcutis Biotherapeutics and 2 mentions for Design Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.18 beat Design Therapeutics' score of 0.94 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has higher revenue and earnings than Design Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.14	-$16.14M	-$0.03	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Arcutis Biotherapeutics currently has a consensus price target of $34.00, indicating a potential upside of 58.43%. Design Therapeutics has a consensus price target of $16.50, indicating a potential upside of 57.44%. Given Arcutis Biotherapeutics' higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Arcutis Biotherapeutics and Design Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Design Therapeutics compare to IDEAYA Biosciences?

Design Therapeutics (NASDAQ:DSGN) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Design Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 57.44%. IDEAYA Biosciences has a consensus price target of $50.69, indicating a potential upside of 72.00%. Given IDEAYA Biosciences' higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

Design Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

Design Therapeutics has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
IDEAYA Biosciences	$218.71M	11.84	-$113.70M	-$1.60	N/A

IDEAYA Biosciences' return on equity of -14.24% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

In the previous week, IDEAYA Biosciences had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 6 mentions for IDEAYA Biosciences and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat IDEAYA Biosciences' score of 0.56 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 23.5% of Design Therapeutics shares are held by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Design Therapeutics beats IDEAYA Biosciences on 8 of the 15 factors compared between the two stocks.

How does Design Therapeutics compare to Vera Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Design Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Design Therapeutics' return on equity of -33.07% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Vera Therapeutics	N/A	-74.86%	-60.18%

In the previous week, Vera Therapeutics had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Vera Therapeutics and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Vera Therapeutics' score of 0.91 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Design Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 57.44%. Vera Therapeutics has a consensus target price of $79.00, indicating a potential upside of 122.41%. Given Vera Therapeutics' higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Design Therapeutics has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 23.5% of Design Therapeutics shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Design Therapeutics beats Vera Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DSGN vs. The Competition

Export

Metric	Design Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$654.58M	$3.40B	$6.41B	$12.58B
Dividend Yield	N/A	2.28%	2.75%	5.26%
P/E Ratio	-8.73	18.88	21.25	26.28
Price / Sales	N/A	334.56	561.56	114.75
Price / Cash	N/A	125.26	43.49	56.90
Price / Book	3.00	7.27	10.60	7.33
Net Income	-$69.79M	$24.20M	$3.56B	$337.06M
7 Day Performance	-4.47%	4.20%	2.98%	3.42%
1 Month Performance	-33.63%	9.56%	6.27%	7.24%
1 Year Performance	161.35%	63.63%	36.76%	37.97%

Design Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DSGN Design Therapeutics	2.8459 of 5 stars	$10.48 -2.4%	$16.50 +57.4%	+168.5%	$654.58M	N/A	N/A	40	High Trading Volume
GPCR Structure Therapeutics	3.3019 of 5 stars	$35.88 -0.6%	$109.25 +204.5%	+80.9%	$2.56B	N/A	N/A	136	Gap Up
IRON Disc Medicine	2.0349 of 5 stars	$64.07 -4.2%	$105.30 +64.4%	+56.9%	$2.55B	N/A	N/A	30
ARQT Arcutis Biotherapeutics	3.5651 of 5 stars	$19.50 -2.6%	$34.00 +74.4%	+57.9%	$2.51B	$376.07M	N/A	150	Positive News High Trading Volume
IDYA IDEAYA Biosciences	3.6343 of 5 stars	$28.32 flat	$50.69 +79.0%	+50.0%	$2.49B	$218.71M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DSGN) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Design Therapeutics (DSGN) Competitors

DSGN vs. GPCR, IRON, ARQT, IDYA, and VERA

How does Design Therapeutics compare to Structure Therapeutics?

Summary

How does Design Therapeutics compare to Disc Medicine?

Summary

How does Design Therapeutics compare to Arcutis Biotherapeutics?

Summary

How does Design Therapeutics compare to IDEAYA Biosciences?

Summary

How does Design Therapeutics compare to Vera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Design Therapeutics (DSGN) Competitors

DSGN vs. GPCR, IRON, ARQT, IDYA, and VERA

How does Design Therapeutics compare to Structure Therapeutics?

Do insiders and institutionals hold more shares of DSGN or GPCR?

Does the media refer more to DSGN or GPCR?

Which has preferable valuation and earnings, DSGN or GPCR?

Do analysts prefer DSGN or GPCR?

Is DSGN or GPCR more profitable?

Which has more volatility and risk, DSGN or GPCR?

Summary

How does Design Therapeutics compare to Disc Medicine?

Do analysts recommend IRON or DSGN?

Do institutionals and insiders believe in IRON or DSGN?

Is IRON or DSGN more profitable?

Does the media favor IRON or DSGN?

Which has higher valuation and earnings, IRON or DSGN?

Which has more risk & volatility, IRON or DSGN?

Summary

How does Design Therapeutics compare to Arcutis Biotherapeutics?

Do insiders & institutionals hold more shares of ARQT or DSGN?

Which has more volatility & risk, ARQT or DSGN?

Is ARQT or DSGN more profitable?

Does the media prefer ARQT or DSGN?

Which has stronger valuation and earnings, ARQT or DSGN?

Do analysts rate ARQT or DSGN?

Summary

How does Design Therapeutics compare to IDEAYA Biosciences?

Do analysts rate DSGN or IDYA?

Which has more volatility and risk, DSGN or IDYA?

Which has stronger earnings and valuation, DSGN or IDYA?

Is DSGN or IDYA more profitable?

Does the media refer more to DSGN or IDYA?

Do institutionals & insiders believe in DSGN or IDYA?

Summary

How does Design Therapeutics compare to Vera Therapeutics?

Which has stronger valuation & earnings, DSGN or VERA?

Is DSGN or VERA more profitable?

Does the media refer more to DSGN or VERA?

Do analysts prefer DSGN or VERA?

Which has more volatility and risk, DSGN or VERA?

Do insiders & institutionals believe in DSGN or VERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools